stockportfolio.pro
Ultragenyx Pharmaceutical Inc. (RARE)
Healthcare · Biotechnology · NasdaqGS
Ultragenyx Pharmaceutical Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133,000 | $2.61M | $51.49M | $103.71M | $271.03M | $351.41M | $363.33M | $434.00M | $560.00M | $673.00M |
| Gross profit | — | $2.61M | $50.35M | — | — | — | $335.01M | $389.00M | $483.00M | $564.00M |
| Net income | $-245.87M | $-302.14M | $-197.61M | $-402.73M | $-186.57M | $-454.02M | $-707.42M | $-607.00M | $-569.00M | $-575.00M |
| Net margin | -184867.7% | -11567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% |
Source: Ultragenyx Pharmaceutical Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Ultragenyx Pharmaceutical Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RARE in your portfolio →
Ultragenyx Pharmaceutical Inc. financial history by metric
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. — frequently asked questions
What is Ultragenyx Pharmaceutical Inc.'s revenue?
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $673.00M for fiscal year 2025, up 20.2% from the prior year, according to its SEC filings.
Is Ultragenyx Pharmaceutical Inc. profitable?
No — RARE reported a net loss of $-575.00M in fiscal 2025.
What is RARE's P/E ratio?
Ultragenyx Pharmaceutical Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ultragenyx Pharmaceutical Inc. growing?
RARE's revenue grew at roughly 19.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ultragenyx Pharmaceutical Inc. have?
As of fiscal year 2025, RARE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ultragenyx Pharmaceutical Inc.'s gross margin?
RARE's gross margin was 83.8% in fiscal 2025 — gross profit of $564.00M on revenue of $673.00M.
What is Ultragenyx Pharmaceutical Inc.'s market cap?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of about $2.27B, based on the latest data in our nightly-refreshed cache.
When does Ultragenyx Pharmaceutical Inc.'s fiscal year end?
RARE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ultragenyx Pharmaceutical Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.